If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Aptar Pharma QuickStart Injectables wins Industry Innovation Award at Pharmapack 2019

    Quick Contact
    • Aptar Pharma
    Aptar Pharma QuickStart Injectables wins Industry Innovation Award at Pharmapack 2019

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that their recently-launched QuickStart™ for Injectables has won Best Innovation in Packaging Material & Component category at the 2019 Pharmapack Awards in Paris, France.

    QuickStart Injectables is a sterile, Ready-To-Use (RTU) drug development offering designed specifically to accelerate the development time for start-ups and early stage development, R&D, biotechs, and university research organizations.

    Aptar Pharma launched this highly-innovative injectable development package in October 2018 at CPhI Worldwide in Madrid.

    Aptar Pharma also announced at Pharmapack 2019 that the award-winning QuickStart development package is now available for online purchase via the Aptar Pharma website utilizing a convenient, easy-to-use configurator, further simplifying access for research scientists and drug developers with a click of a button. QuickStart comes with several other key scientific benefits.

    QuickStart Injectables provides a one-stop packaging solution, which allows developers to focus on their science and chemistry. QuickStart arrives RTU to the point of use, which reduces the number of human/product interactions while at the same time optimizing manufacturing productivity, as the vials, stoppers, and caps can be used immediately upon receipt and directly introduced into restricted access barrier systems (RABS) or isolators.

    QuickStart Injectables comes with gamma-sterilized stoppers and push-off caps, and ETO-sterilized vials to provide customers with better quality, real flexibility, convenience, and speed. The package, complete with glass vials from Schott, elastomeric stoppers from Aptar Pharma and push-off caps from EMA Pharmaceuticals, provides everything needed for the small-volume filling of high value formulations.

    QuickStart Injectables is also able to cater to different sizes and configurations of vials, stoppers, and caps. The offering also includes all of the quality and technical documentation required to verify the sterilization and compatibility (CCI) of components, which serves to proactively address regulators’ needs and accelerate approval.

    Bas Van Buijtenen, President of the Aptar Pharma Injectables Division, comments, “We are delighted that QuickStart Injectables has won ‘Best Innovation in Packaging Material & Component’ at this year’s Pharmapack Awards. With QuickStart, we are enabling small scale sterile fills for innovative drug companies. Because we offer a small scale packaging solution identical to what will be used for large scale fills, these innovators gain reliability and time in their drug development pipeline.”

    Adam Shain, Aptar Pharma’s Director, Global Business Development – Injectables, adds “Winning the Pharmapack innovation award is a recognition of an industry need for fast development solutions. QuickStart Injectables is all about convenience, speed, and quality by enabling companies to have a quick and positive development experience. This need for speed and convenience is what drove us to make QuickStart available online, because we recognized that when developers are starting out, it is not always obvious how to procure the packaging they require.

    The success of QuickStart Injectables demonstrates a true team effort bringing together the best solutions from Schott, Aptar Pharma, and EMA Pharmaceuticals. Together, we are able to deliver a robust and easy-to-use solution, which lets our pharmaceutical partners focus on the drug product, while we take care of the packaging. I look forward to the continued success of Aptar Pharma QuickStart”.

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Isabel Thomas
    • Product Info
    • English
    • Created 07 Feb 2019
    • Modified 12 Apr 2019
    • Hits 1019
    SR Packaging
    Webpackaging
    Conzept International